Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Katie Gresham

Nurse Practitioner, Family Evans, GA Nurse Practitioner

NPI 1003589631 CMS profile 10964647

4720 Washington Rd, Evans, GA 30809

Open in the dashboard

General payments

$10,452

452 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katie Gresham of Evans, GA is reported in the CMS Open Payments database as having received $10,452 across 452 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,428 113
2024 General $1,979 94
2023 General $2,289 113
2022 General $3,386 110
2021 General $370 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katie Gresham
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Katie Gresham were reported at $2,428. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Katie Gresham Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $370 $124 $35–$379 $132
2022 $3,386 $141 $44–$430 $149
2023 $2,289 $154 $49–$476 $160
2024 $1,979 $165 $51–$504 $164
2025 $2,428 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Mannkind Corporation $1,682 14 payments
  2. Lilly USA, LLC $1,028 49 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $736 39 payments
  4. Novo Nordisk Inc $700 37 payments
  5. Corcept Therapeutics $565 24 payments
  6. Amgen Inc. $528 28 payments
  7. Dexcom, Inc. $490 29 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $449 27 payments
  9. Xeris Pharmaceuticals, Inc. $431 22 payments
  10. Sanofi-Aventis U.S. LLC $416 16 payments
  11. Other $3,427 167 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,000 448 payments
  2. Travel and Lodging $855 3 payments
  3. Consulting Fee $597 1 payment
Products named General payments · program years 2021–2025
  1. AFREZZA $1,682 14 payments
  2. Kerendia $736 39 payments
  3. Ozempic $664 35 payments
  4. MOUNJARO $621 28 payments
  5. Korlym $565 24 payments
  6. Dexcom G6 Transmitter $468 28 payments
  7. XYOSTED $460 28 payments
  8. RYBELSUS $404 25 payments
  9. TZIELD $398 15 payments
  10. MINIMED 780G $379 12 payments
  11. Other $6,173 327 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

1,563

Median for Nurse Practitioner: 389

Drug cost

$922,990

Median for Nurse Practitioner: $21,885

Branded share of claims

78.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 146 $181,976
Ozempic Semaglutide Brand 115 $172,923
Jardiance Empagliflozin Brand 89 $112,704
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 17 $63,890
Trulicity Dulaglutide Brand 45 $61,011
Tresiba Flextouch U-100 Insulin Degludec Brand 76 $52,307
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 37 $45,032
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 26 $25,650
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 16 $23,805
Farxiga Dapagliflozin Propanediol Brand 19 $23,589

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$35,590

Medicare's payments for the services billed

Medicare patients

229

Average age 74

Services billed

1,316

140 women, 89 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 48%
Ischemic heart disease 44%
Arthritis 44%
Heart failure 24%
Depression 19%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $131
  • Lilly USA, LLC $117
$248 89 —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $242
$242 — —
MOUNJARO
  • Lilly USA, LLC $162
$162 146 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $126
$126 — —
Korlym
  • Corcept Therapeutics $74
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

452 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record